Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lanzhou Univ. BRD4 compound 27d
- Development stage
- Unknown
- Lead developer
- Lanzhou University
01
Overview
Lanzhou Univ. BRD4 compound 27d: sourced facts only. name: "Among them, the representative compound 27d showed excellent BRD4 inhibitory activities with an IC50 value of 99 nM in the TR-FRET assay." [PMID:36063752]; target: "Among them, the representative compound 27d showed excellent BRD4 inhibitory activities with an IC50 value of 99 nM in the TR-FRET assay." [PMID:36063752]; developer: "School of Pharmacy, Lanzhou University, Lanzhou 730000, China." [PMID:36063752]
02
Targets
BRD4 (Bromodomain-containing protein 4)
Beyond the preview
Go deeper on Lanzhou Univ. BRD4 compound 27d.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lanzhou Univ. BRD4 compound 27d.